Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients
Introduction: No therapy has proven to be effective yet to reduce mortality and/or invasive mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. Methods: We conducted a retrospective case-control study in the Nord F...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-10-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971220306536 |
| _version_ | 1818333756153397248 |
|---|---|
| author | Timothée Klopfenstein Souheil Zayet Anne Lohse Phillippe Selles Hajer Zahra N’dri Juliette Kadiane-Oussou Lynda Toko Pierre-Yves Royer Jean-Charles Balblanc Vincent Gendrin Thierry Conrozier |
| author_facet | Timothée Klopfenstein Souheil Zayet Anne Lohse Phillippe Selles Hajer Zahra N’dri Juliette Kadiane-Oussou Lynda Toko Pierre-Yves Royer Jean-Charles Balblanc Vincent Gendrin Thierry Conrozier |
| author_sort | Timothée Klopfenstein |
| collection | DOAJ |
| description | Introduction: No therapy has proven to be effective yet to reduce mortality and/or invasive mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. Methods: We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: mortality and/or IMV requirement. Results: Thirty patients were treated with TCZ and 176 patients were treated without TCZ. TCZ was used in patients in critical condition (oxygen therapy flow at TCZ onset was 10.5 L/min and 14/30 patients had ≥ 50% lung involvement on CT scan) as a rescue treatment (8/30 patients who died were not admitted in USC in regard to their comorbidities). However, mortality and/or IMV requirement were lower in patients with TCZ than in patients without TCZ (27% vs 52%, p = 0.009). Conclusion: Despite the small sample size in the TCZ group, this result suggests that TCZ reduces mortality and/or IMV requirement in patients with severe SARS-CoV-2 pneumonia. This notion needs to be confirmed and spread in the medical community. |
| first_indexed | 2024-12-13T13:56:41Z |
| format | Article |
| id | doaj.art-211ce617ac594aca973c24253504e282 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-13T13:56:41Z |
| publishDate | 2020-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-211ce617ac594aca973c24253504e2822022-12-21T23:42:52ZengElsevierInternational Journal of Infectious Diseases1201-97122020-10-0199491495Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patientsTimothée Klopfenstein0Souheil Zayet1Anne Lohse2Phillippe Selles3Hajer Zahra4N’dri Juliette Kadiane-Oussou5Lynda Toko6Pierre-Yves Royer7Jean-Charles Balblanc8Vincent Gendrin9Thierry Conrozier10Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France; Corresponding authors at: Department of Infectious Disease, Nord Franche-Comté Hospital, 90400 Trevenans, France.Infectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, France; Corresponding authors at: Department of Infectious Disease, Nord Franche-Comté Hospital, 90400 Trevenans, France.Rheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, FranceMedical Information Department, Nord Franche-Comté Hospital, 90400 Trévenans, FranceDiabetology and Endocrinology Department, Nord Franche-Comté Hospital, 90400 Trévenans, FranceInfectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, FranceInfectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, FranceInfectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, FranceRheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, FranceInfectious Disease Department, Nord Franche-Comté Hospital, 90400 Trévenans, FranceRheumatology Department, Nord Franche-Comté Hospital, 90400 Trévenans, FranceIntroduction: No therapy has proven to be effective yet to reduce mortality and/or invasive mechanical ventilation (IMV) requirement in COVID-19. Tocilizumab (TCZ) in patients with severe COVID-19 could be an effective treatment. Methods: We conducted a retrospective case-control study in the Nord Franche-Comté Hospital, France. We compared the outcome of patients treated with TCZ and patients without TCZ considering a combined primary endpoint: mortality and/or IMV requirement. Results: Thirty patients were treated with TCZ and 176 patients were treated without TCZ. TCZ was used in patients in critical condition (oxygen therapy flow at TCZ onset was 10.5 L/min and 14/30 patients had ≥ 50% lung involvement on CT scan) as a rescue treatment (8/30 patients who died were not admitted in USC in regard to their comorbidities). However, mortality and/or IMV requirement were lower in patients with TCZ than in patients without TCZ (27% vs 52%, p = 0.009). Conclusion: Despite the small sample size in the TCZ group, this result suggests that TCZ reduces mortality and/or IMV requirement in patients with severe SARS-CoV-2 pneumonia. This notion needs to be confirmed and spread in the medical community.http://www.sciencedirect.com/science/article/pii/S1201971220306536COVID-19SARS-CoV-2TocilizumabMortalityInvasive mechanical ventilation |
| spellingShingle | Timothée Klopfenstein Souheil Zayet Anne Lohse Phillippe Selles Hajer Zahra N’dri Juliette Kadiane-Oussou Lynda Toko Pierre-Yves Royer Jean-Charles Balblanc Vincent Gendrin Thierry Conrozier Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients International Journal of Infectious Diseases COVID-19 SARS-CoV-2 Tocilizumab Mortality Invasive mechanical ventilation |
| title | Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients |
| title_full | Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients |
| title_fullStr | Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients |
| title_full_unstemmed | Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients |
| title_short | Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients |
| title_sort | impact of tocilizumab on mortality and or invasive mechanical ventilation requirement in a cohort of 206 covid 19 patients |
| topic | COVID-19 SARS-CoV-2 Tocilizumab Mortality Invasive mechanical ventilation |
| url | http://www.sciencedirect.com/science/article/pii/S1201971220306536 |
| work_keys_str_mv | AT timotheeklopfenstein impactoftocilizumabonmortalityandorinvasivemechanicalventilationrequirementinacohortof206covid19patients AT souheilzayet impactoftocilizumabonmortalityandorinvasivemechanicalventilationrequirementinacohortof206covid19patients AT annelohse impactoftocilizumabonmortalityandorinvasivemechanicalventilationrequirementinacohortof206covid19patients AT phillippeselles impactoftocilizumabonmortalityandorinvasivemechanicalventilationrequirementinacohortof206covid19patients AT hajerzahra impactoftocilizumabonmortalityandorinvasivemechanicalventilationrequirementinacohortof206covid19patients AT ndrijuliettekadianeoussou impactoftocilizumabonmortalityandorinvasivemechanicalventilationrequirementinacohortof206covid19patients AT lyndatoko impactoftocilizumabonmortalityandorinvasivemechanicalventilationrequirementinacohortof206covid19patients AT pierreyvesroyer impactoftocilizumabonmortalityandorinvasivemechanicalventilationrequirementinacohortof206covid19patients AT jeancharlesbalblanc impactoftocilizumabonmortalityandorinvasivemechanicalventilationrequirementinacohortof206covid19patients AT vincentgendrin impactoftocilizumabonmortalityandorinvasivemechanicalventilationrequirementinacohortof206covid19patients AT thierryconrozier impactoftocilizumabonmortalityandorinvasivemechanicalventilationrequirementinacohortof206covid19patients |